Axogen to Participate in Four Investor Conferences in September

Axogen, a global leader in surgical solutions for peripheral nerve function, announced its management participation in four investor conferences. The events include a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference and Morgan Stanley Annual Global Healthcare Conference, as well as 1x1 investor meetings at the Wells Fargo Healthcare Conference and Lake Street Best Ideas Growth Conference. Webcasts of the events will be available on the company's website.

Axogen, Inc. (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve function, has announced its management's participation in four upcoming investor conferences in September 2025. The events include a fireside chat and one-on-one investor meetings at the Cantor Global Healthcare Conference and Morgan Stanley Annual Global Healthcare Conference, as well as one-on-one investor meetings at the Wells Fargo Healthcare Conference and Lake Street Best Ideas Growth Conference.

The Cantor Global Healthcare Conference, taking place on September 3, 2025, at 3:20 PM ET, will feature a fireside chat with Axogen management, which will be available via webcast. Additionally, one-on-one investor meetings will be conducted at the Wells Fargo Healthcare Conference on September 4, the Morgan Stanley Annual Global Healthcare Conference on September 10, and the Lake Street Best Ideas Growth Conference on September 11.

All webcast events will be accessible through Axogen's investor relations website and archived for 90 days. This provides investors with ample opportunities to engage with Axogen's management and gain insights into the company's strategic direction and product pipeline.

Axogen's portfolio includes products such as Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™, designed to assist in the treatment of peripheral nerve injuries. The company's focus on innovative, clinically proven, and economically effective repair solutions has positioned it as a leader in the field of peripheral nerve regeneration and repair.

In addition to these conference announcements, Axogen has recently received an extension for its Biologics License Application (BLA) for Avance® Nerve Graft. The FDA has extended the PDUFA goal date to December 5, 2025, to allow for additional review of substantial new manufacturing and facility data submitted by the company. This extension follows a communication from the FDA indicating that the information submitted is considered a Major Amendment to the BLA, allowing for additional review time [2].

Axogen's management has expressed appreciation for the FDA's thorough review and looks forward to continuing its engagement with the agency to complete the transition of Avance Nerve Graft from a tissue product to a BLA-approved biologic. This development underscores the company's commitment to regulatory compliance and the advancement of its product portfolio.

Investors are encouraged to tune in to the upcoming investor conferences and webcasts to gain a deeper understanding of Axogen's strategic initiatives and product developments. For more information, visit Axogen's investor relations website.

References:
[1] https://www.stocktitan.net/news/AXGN/axogen-inc-to-participate-in-multiple-upcoming-investor-ei6zwijp2xws.html
[2] https://finance.yahoo.com/news/axogen-provides-fda-review-timeline-104000348.html